Pfizer (PFE) Tops Q4 EPS by 1c, FY EPS Guidance Misses Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2018 RESULTS
January 29, 2019 6:45 AM ESTPROVIDES 2019 FINANCIAL GUIDANCE
Full-Year 2018 Revenues of $53.6 Billion, Reflecting 2% Operational Growth; Fourth-Quarter 2018 Revenues of $14.0 Billion, Reflecting 5% Operational Growth Full-Year 2018 Reported Diluted EPS(1) of $1.87, Adjusted Diluted EPS(2) of $3.00; Fourth-Quarter 2018 Reported Loss Per Share(1) of $0.07, Adjusted Diluted EPS(2) of $0.64 Returned $20.2 Billion Directly to Shareholders in 2018 Through Share Repurchases and Dividends; Anticipates Repurchasing Approximately $9 Billion of Shares in 2019 Provides 2019 Financial Guidance Reflects a Full Year of Revenue and Expense Contributions from Consumer Healthcare(3) Reflects Anticipated Unfavorable Impact of Foreign Exchange of... More